Sundar Pichai Says 'Every Cell In Our Body Shares the Same DNA Blueprint' as Google DeepMind Unveils AlphaGenome 2 Amid Drugmakers' AI Skepticism

What happened

Google DeepMind announced AlphaGenome 2, an AI model designed to predict how DNA variations affect specific cell types and help researchers study disease mechanisms. The company said it used more than 107 million human and mouse cell profiles to train the model, which found nearly twice as many gene-expression-changing variants as its previous model.

Confirmed

Global impact / market context

If the model helps researchers identify disease-related DNA changes more accurately, it could make early biological research more useful for drug development. That may influence how drugmakers allocate research spending, but the article does not establish that the tool improves clinical results or reduces development costs.

Analyst inference

The article presents a technical advance amid drugmakers’ skepticism about AI, but gives no evidence of commercial adoption, revenue, or investor response. For Alphabet, any financial effect would depend on researchers using the model and its findings translating into useful drug research.

Analyst inference

What to watch

1. Look for further benchmark results showing whether AlphaGenome 2’s improved variant identification holds across cell types, beyond the immune-cell comparison described in the article. Analyst inference
2. Watch for evidence that drugmakers or research teams use the model in active drug-discovery projects; the article announces a research tool, not commercial uptake. Analyst inference
3. The article says the model can adapt to new single-cell data without retraining, which could make analysis of newly studied cell states more practical for researchers. Confirmed

Evidence

• Original source link unavailable